EUVIMEDEUVIMED entdecken
VergleichsstudieMultizentrische StudieBeobachtungsstudie

Drug‐Coated Balloon Versus Drug‐Eluting Stent for Femoropopliteal Lesions: A 3‐Year Propensity Score‐Matched Analysis

Osamu Iida, Mitsuyoshi Takahara, Yoshimitsu Soga iD, Yusuke Tomoi iD, Daizo Kawasaki, Masahiko Fujihara, Amane Kozuki iD, Akiko Tanaka iD, Yasutaka Yamauchi, Kazuki Tobita, Terutoshi Yamaoka, Shigeo Ichihashi und 2 weitere

Catheterization and Cardiovascular Interventions · 16.07.2026

DOI: 10.1002/ccd.70750 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Catheterization and Cardiovascular Interventions, online erschienen am 16.07.2026. Verfasst von Osamu Iida und 13 weiteren Autor:innen. Beteiligte Einrichtung: Cardiovascular Division, Osaka Keisatsu Hospital, Osaka, Japan. Hauptthemen laut MEDLINE: Angioplasty, Balloon, Cardiovascular Agents, Coated Materials, Biocompatible, Drug-Eluting Stents. Die Arbeit nennt 11 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

While drug‐eluting treatment is a first‐line therapy for femoropopliteal (FP) lesions, long‐term comparative data between drug‐eluting stents (DES) and drug‐coated balloons (DCB) in real‐world practice are scarce. We aimed to compare the 3‐year outcomes of DES versus DCB for symptomatic FP disease.

Methods

We conducted a retrospective analysis of the CILANTRO study, a multicenter registry combining data from the CAPSICUM, POPCORN, and POPCORN Type R studies. Patients treated with either DES or DCB for symptomatic FP lesions were included. To minimize selection bias, we performed 1:1 propensity score matching. The primary outcome was clinically driven target lesion revascularization (TLR), while secondary outcomes included restenosis.

Results

A total of 2651 patients treated with DCB and 972 with DES were identified. Propensity score matching extracted 912 pairs with well‐balanced baseline characteristics. The median follow‐up period was 31.6 months. The 3‐year rate of TLR was not significantly different between the DCB and DES groups (23.3% vs. 18.8%; hazard ratio, 1.19 [95% confidence interval, 0.93–1.53]; p = 0.16). Interaction analysis revealed that a more marked increased risk of TLR in the DCB group in patients with semi‐compliant balloon use or without non‐compliant balloon use ( p = 0.017 and 0.018). The 3‐year rate of restenosis was significantly higher in the DCB group than in the DES group (38.1% vs. 26.3%; hazard ratio, 1.77 [1.43–2.19]; p < 0.001).

Conclusions

In this propensity score‐matched analysis, the 3‐year rate of TLR was not significantly different between DCB and DES, although DES demonstrated lower restenosis rate. Nevertheless, DCB remains a clinically viable option, and our sub‐analysis suggests that balloon selection for pre‐dilatation may influence its efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Angioplasty, BalloonCardiovascular AgentsCoated Materials, BiocompatibleDrug-Eluting StentsFemoral ArteryPeripheral Arterial DiseasePopliteal ArteryAgedFemaleHumansMaleMiddle AgedPropensity ScoreProsthesis DesignRecurrenceRegistriesRetrospective StudiesRisk AssessmentRisk FactorsTime FactorsTreatment OutcomeVascular Access DevicesVascular Patency

Stichwörter der Autor:innen

drug‐coated balloondrug‐eluting stentfemoropopliteal arteryperipheral arterial diseasetarget lesion revascularization

Substanzen

Cardiovascular AgentsCoated Materials, Biocompatible

Autor:innen und Institutionen

  • Cardiovascular Division, Osaka Keisatsu Hospital, Osaka, Japan.
  • Department of Metabolic Medicine, Osaka University Graduate School of Medicine, Suita, Japan.
  • Department of Laboratory Medicine, The University of Osaka Graduate School of Medicine, Suita, Japan.
  • Department of Cardiology, Kokura Memorial Hospital, Kitakyushu, Japan.
  • Department of Cardiology, Morinomiya Hospital, Osaka, Japan.
  • Department of Cardiology, Kishiwada Tokushukai Hospital, Kishiwada, Japan.

ORCID-Profile: Yoshimitsu Soga, Yusuke Tomoi, Amane Kozuki, Akiko Tanaka

Zitieren

APA

Iida, O., Takahara, M., Soga, Y., Tomoi, Y., Kawasaki, D., Fujihara, M., Kozuki, A., Tanaka, A., Yamauchi, Y., Tobita, K., Yamaoka, T., Ichihashi, S., Sakata, Y., & CILANTRO investigators (2026). Drug‐Coated Balloon Versus Drug‐Eluting Stent for Femoropopliteal Lesions: A 3‐Year Propensity Score‐Matched Analysis. Catheterization and Cardiovascular Interventions. https://doi.org/10.1002/ccd.70750

Vancouver

Iida O, Takahara M, Soga Y, Tomoi Y, Kawasaki D, Fujihara M, et al. Drug‐Coated Balloon Versus Drug‐Eluting Stent for Femoropopliteal Lesions: A 3‐Year Propensity Score‐Matched Analysis. Catheterization and Cardiovascular Interventions. 2026. doi:10.1002/ccd.70750

BibTeX
@article{Iida2026,
  author = {Iida, Osamu and Takahara, Mitsuyoshi and Soga, Yoshimitsu and Tomoi, Yusuke and Kawasaki, Daizo and Fujihara, Masahiko and Kozuki, Amane and Tanaka, Akiko and Yamauchi, Yasutaka and Tobita, Kazuki and Yamaoka, Terutoshi and Ichihashi, Shigeo and Sakata, Yasushi and CILANTRO investigators, CILANTRO investigators},
  title = {Drug‐Coated Balloon Versus Drug‐Eluting Stent for Femoropopliteal Lesions: A 3‐Year Propensity Score‐Matched Analysis},
  journal = {Catheterization and Cardiovascular Interventions},
  year = {2026},
  doi = {10.1002/ccd.70750}
}
Kostenlos starten →